Last reviewed · How we verify
Levamlodipine besylate
Levamlodipine besylate is the active L-enantiomer of amlodipine that blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reducing blood pressure.
Levamlodipine besylate is the active L-enantiomer of amlodipine that blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reducing blood pressure. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Levamlodipine besylate |
|---|---|
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Drug class | Dihydropyridine calcium channel blocker |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
As a dihydropyridine calcium channel blocker, levamlodipine selectively inhibits calcium influx through L-type voltage-gated calcium channels in the cell membrane of vascular smooth muscle cells. This prevents calcium-dependent contraction, leading to vasodilation of coronary and peripheral arteries, reduced peripheral vascular resistance, and decreased blood pressure. The L-enantiomer is the pharmacologically active form and may offer improved efficacy and tolerability compared to the racemic mixture.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Peripheral edema
- Headache
- Flushing
- Dizziness
- Palpitations
Key clinical trials
- Analysis of Factors Influencing the Efficacy of Levamlodipine Benzoate and Its Population Pharmacodynamic Modeling
- Population Pharmacokinetic - Pharmacodynamic Models of Chronic Disease Therapeutics for Smokers
- Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects (PHASE1)
- Bioequivalence Evaluation of Two Fixed-dose Combination of Lisinopril 10mg/Levamlodipine Besylate 5mg in Healthy Chinese Subjects (PHASE1)
- Bioequivalence of Levamlodipine Besylate Tablets in Healthy Chinese Subjects (PHASE1)
- Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=27) (PHASE1)
- Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60) (PHASE1)
- Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levamlodipine besylate CI brief — competitive landscape report
- Levamlodipine besylate updates RSS · CI watch RSS
- Jiangsu Simcere Pharmaceutical Co., Ltd. portfolio CI